Use of antidepressants and statins and short-term risk of new-onset diabetes among high risk adults

Diabetes Research and Clinical Practice

Volumn 105, Issue 2, 2014, Pages 251-260

  Bhattacharya, Rituparna ^a   Ajmera, Mayank ^a   Bhattacharjee, Sandipan ^a   Sambamoorthi, Usha ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Antidepressants; New onset diabetes; Statins

Indexed keywords

ANTIDEPRESSANT AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG USE; FEMALE; HIGH RISK POPULATION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NEW ONSET DIABETES; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

ANTIDEPRESSANTS; NEW-ONSET DIABETES; STATINS;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; DEPRESSION; DIABETES MELLITUS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; LIFE STYLE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RESEARCH DESIGN; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84906043374     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.04.016     Document Type: Article

References (63)

1. Statistics National Center for Health Health, United States, 2010: With special feature on death and dying 2011, National Center for Health, MD, Table 95.
2. LaRosa J.C., He J., Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999, 282:2340-2346.
3. Mills E.J., Rachlis B., Wu P., Devereaux P.J., Arora P., Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 2008, 52:1769-1781.
4. Walsh J.M., Pignone M. Drug treatment of hyperlipidemia in women. JAMA 2004, 291:2243-2252.
5. Kornegay C.J., Vasilakis-Scaramozza C., Jick H. Incident diabetes associated with antipsychotic use in the United Kingdom general practice research database. J Clin Psychiatry 2002, 63:758-762.
6. Skevington S.M., Wright A. Changes in the quality of life of patients receiving antidepressant medication in primary care: validation of the WHOQOL-100. Br J Psychiatry 2001, 178:261-267.
7. Derijks H.J., Meyboom R.H., Heerdink E.R., De Koning F.H., Janknegt R., Lindquist M., et al. The association between antidepressant use and disturbances in glucose homeostasis: evidence from spontaneous reports. Eur J Clin Pharmacol 2008, 64:531-538.
8. Levkovitz Y., Ben-Shushan G., Hershkovitz A., Isaac R., Gil-Ad I., Shvartsman D., et al. Antidepressants induce cellular insulin resistance by activation of IRS-1 kinases. Mol Cell Neurosci 2007, 36:305-312.
9. Sussman N., Ginsberg D.L., Bikoff J. Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials. J Clin Psychiatry 2001, 62:256-260.
10. Zimmermann U., Kraus T., Himmerich H., Schuld A., Pollmacher T. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res 2003, 37:193-220.
11. Sukhija R., Prayaga S., Marashdeh M., Bursac Z., Kakar P., Bansal D., et al. Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. J Investig Med 2009, 57:495-499.
12. Sattar N., Preiss D., Murray H.M., Welsh P., Buckley B.M., de Craen A.J., et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010, 375:735-742.
13. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M., Kastelein J.J., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
14. Simsek S., Schalkwijk C.G., Wolffenbuttel B.H. Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes-the CORALL study. Diabet Med 2012, 29:628-631.
15. Culver A.L., Ockene I.S., Balasubramanian R., Olendzki B.C., Sepavich D.M., Wactawski-Wende J., et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 2012, 172:144-152.
16. Rubin R.R., Ma Y., Marrero D.G., Peyrot M., Barrett-Connor E.L., Kahn S.E., et al. Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. Diabetes Care 2008, 31:420-426.
17. Andersohn F., Schade R., Suissa S., Garbe E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry 2009, 166:591-598.
18. Kivimaki M., Batty G.D., Jokela M., Ebmeier K.P., Vahtera J., Virtanen M., et al. Antidepressant medication use and risk of hyperglycemia and diabetes mellitus: a noncausal association. Biol Psychiatry 2011, 70:978-984.
19. Kivimaki M., Hamer M., Batty G.D., Geddes J.R., Tabak A.G., Pentti J., et al. Antidepressant medication use, weight gain, and risk of type 2 diabetes: a population-based study. Diabetes Care 2010, 33:2611-2616.
20. Ma Y., Balasubramanian R., Pagoto S.L., Schneider K.L., Culver A.L., Olendzki B., et al. Elevated depressive symptoms, antidepressant use, and diabetes in a large multiethnic national sample of postmenopausal women. Diabetes Care 2011, 34:2390-2392.
21. Pan A., Sun Q., Okereke O.I., Rexrode K.M., Rubin R.R., Lucas M., et al. Use of antidepressant medication and risk of type 2 diabetes: results from three cohorts of US adults. Diabetologia 2012, 55:63-72.
22. Bhattacharjee S., Bhattacharya R., Kelley G.A., Sambamoorthi U. Antidepressant use and new-onset diabetes: a systematic review and meta-analysis. Diabetes Metab Res Rev 2013, 29:273-284.
23. Barnard K., Peveler R.C., Holt R.I. Antidepressant medication as a risk factor for type 2 diabetes and impaired glucose regulation: systematic review. Diabetes Care 2013, 36:3337-3345.
24. Yoon J.M., Cho E.G., Lee H.K., Park S.M. Antidepressant use and diabetes mellitus risk: a meta-analysis. Korean J Family Med 2013, 34:228-240.
25. Sambamoorthi U., Ma Y., Findley P.A., Rust G. Antidepressant use, depression, and new onset diabetes among elderly medicare beneficiaries. J Diabetes 2012.
26. Wilkins T.L., Sambamoorthi U. Antidepressant use, depression, lifestyle factors, and new-onset diabetes. Int Clin Psychopharmacol 2011, 26:159-168.
27. Freeman D.J., Norrie J., Sattar N., Neely R.D., Cobbe S.M., Ford I., et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001, 103:357-362.
28. Rajpathak S.N., Kumbhani D.J., Crandall J., Barzilai N., Alderman M., Ridker P.M. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009, 32:1924-1929.
29. Rashid M., Tawara S., Fukumoto Y., Seto M., Yano K., Shimokawa H. Importance of Rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors. Circ J 2009, 73:361-370.
30. Ueda S., Kitazawa S., Ishida K., Nishikawa Y., Matsui M., Matsumoto H., et al. Crucial role of the small GTPase Rac1 in insulin-stimulated translocation of glucose transporter 4 to the mouse skeletal muscle sarcolemma. FASEB J 2010, 24:2254-2261.
31. Carvalho F., Barros D., Silva J., Rezende E., Soares M., Fregoneze J., et al. Hyperglycemia induced by acute central fluoxetine administration: role of the central CRH system and 5-HT3 receptors. Neuropeptides 2004, 38:98-105.
32. Sugimoto Y., Inoue K., Yamada J. Involvement of serotonin in zimelidine-induced hyperglycemia in mice. Biol Pharm Bull 1999, 22:1240-1241.
33. Yamada J., Sugimoto Y., Inoue K. Selective serotonin reuptake inhibitors fluoxetine and fluvoxamine induce hyperglycemia by different mechanisms. Eur J Pharmacol 1999, 382:211-215.
34. Chaouloff F., Gunn S.H., Young J.B. Central 5-hydroxytryptamine 2 receptors are involved in the adrenal catecholamine-releasing and hyperglycemic effects of the 5-hydroxytryptamine indirect agonist d-fenfluramine in the conscious rat. J Pharmacol Exp Ther 1992, 260:1008-1016.
35. Chaouloff F., Laude D., Baudrie V. Effects of the 5-HT1C/5-5-HT2 receptor agonists DOI and alpha-methyl-5-HT on plasma glucose and insulin levels in the rat. Eur J Pharmacol 1990, 187:435-443.
36. Jindal R.D. Long-term antidepressant use and risk for diabetes: cause for concern and optimism. Am J Psychiatry 2009, 166:1065-1066. author reply 6.
37. Stanton T., Bolden-Watson C., Cusack B., Richelson E. Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics. Biochem Pharmacol 1993, 45:2352-2354.
38. Skene D.J., Bojkowski C.J., Arendt J. Comparison of the effects of acute fluvoxamine and desipramine administration on melatonin and cortisol production in humans. Br J Clin Pharmacol 1994, 37:181-186.
39. Xia F., Xie L., Mihic A., Gao X., Chen Y., Gaisano H.Y., et al. Inhibition of cholesterol biosynthesis impairs insulin secretion and voltage-gated calcium channel function in pancreatic beta-cells. Endocrinology 2008, 149:5136-5145.
40. Chamberlain L.H. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett 2001, 507:357-361.
41. Nakata M., Nagasaka S., Kusaka I., Matsuoka H., Ishibashi S., Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 2006, 49:1881-1892.
42. Kwak H.B., Thalacker-Mercer A., Anderson E.J., Lin C.T., Kane D.A., Lee N.S., et al. Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes. Free Radic Biol Med 2012, 52:198-207.
43. Galtier F., Mura T., Raynaud de Mauverger E., Chevassus H., Farret A., Gagnol J.P., et al. Effect of a high dose of simvastatin on muscle mitochondrial metabolism and calcium signaling in healthy volunteers. Toxicol Appl Pharmacol 2012, 263:281-286.
44. Kusminski C.M., Scherer P.E. Mitochondrial dysfunction in white adipose tissue. Trends Endocrinol Metab 2012, 23:435-443.
45. Hoeks J., Schrauwen P. Muscle mitochondria and insulin resistance: a human perspective. Trends Endocrinol Metab 2012, 23:444-450.
46. Supale S., Li N., Brun T., Maechler P. Mitochondrial dysfunction in pancreatic beta cells. Trends Endocrinol Metab 2012, 23:477-487.
47. Tatonetti N.P., Denny J.C., Murphy S.N., Fernald G.H., Krishnan G., Castro V., et al. Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels. Clin Pharmacol Ther 2011, 90:133-142.
48. Sowers J.R., Epstein M., Frohlich E.D. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001, 37:1053-1059.
49. National Diabetes Information Clearinghouse. Diabetes Prevention Program. Who should be tested for prediabetes and diabetes? [accessed 19.01.14]. http://diabetes.niddk.nih.gov/dm/pubs/preventionprogram/.
50. Agency of Healthcare Research and Quality. Medical Expenditure Panel Survey Data Documentation. [accessed 30.05.13]. http://meps.ahrq.gov/mepsweb/survey_comp/mpc_data_collection.jsp.
51. Agency of Healthcare Research and Quality. Medical Expenditure Panel Survey. MEPS HC-126A: 2009 Prescribed Medicines. [accessed 20.01.14]. http://meps.ahrq.gov/mepsweb/data_stats/download_data/pufs/h126a/h126adoc.pdf.
52. Agency of Healthcare Research and Quality. Medical Expenditure Panel Survey Longitudinal Data File Documentation. [accessed 30.01.13]. http://meps.ahrq.gov/mepsweb/data_stats/download_data_files_results.jsp%3FcboDataYear=All%26cboDataTypeY=1%2CHousehold+Full+Year+File%26buttonYearandDataType=Search%26cboPufNumber=All%26SearchTitle=Longitudinal.
53. MacHlin S., Cohen J., Elixhauser A., Beauregard K., Steiner C. Sensitivity of household reported medical conditions in the medical expenditure panel survey. Med Care 2009, 47:618-625.
54. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
55. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., Laakso M., et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002, 359:2072-2077.
56. Gerstein H.C., Yusuf S., Bosch J., Pogue J., et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006, 368:1096-1105. Investigators D.T.
57. Atlantis E., Browning C., Sims J., Kendig H. Diabetes incidence associated with depression and antidepressants in the Melbourne Longitudinal Studies on Healthy Ageing (MELSHA). Int J Geriatr Psychiatry 2010, 25:688-696.
58. Knol M.J., Geerlings M.I., Egberts A.C., Gorter K.J., Grobbee D.E., Heerdink E.R. No increased incidence of diabetes in antidepressant users. Int Clin Psychopharmacol 2007, 22:382-386.
59. Hennings J.M., Schaaf L., Fulda S. Glucose metabolism and antidepressant medication. Curr Pharm Des 2012, 18:5900-5919.
60. Sampson U.K., Linton M.F., Fazio S. Are statins diabetogenic. Curr Opin Cardiol 2011, 26:342-347.
61. Collins R., Armitage J., Parish S., Sleigh P., Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361:2005-2016.
62. Keech A., Colquhoun D., Best J., Kirby A., Simes R.J., Hunt D., et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003, 26:2713-2721.
63. Kjekshus J., Apetrei E., Barrios V., Böhm M., Cleland J.G.F., Cornel J.H., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007, 357:2248-2261.